The FDA has approved Epioxa, a noninvasive epithelium-on corneal cross-linking treatment for keratoconus, which aims to enhance patient comfort and reduce recovery time.
Background
Keratoconus is a progressive eye disease that can lead to significant visual impairment if not diagnosed and treated early. The introduction of new treatment options, such as Epioxa, represents a significant advancement in managing this condition, particularly for young patients who are often diagnosed at an early age.
Data Highlights
Study
Change from Baseline (D)
Month
P-value
Study 1
-1.0
6
<0.01
Study 1
-1.1
12
<0.01
Study 2
-1.0
12
<0.01
Key Findings
Epioxa is the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus.
The treatment is indicated for patients aged 13 years and older.
In clinical trials, Epioxa demonstrated statistically significant improvements in Kmax compared to sham treatments.
The most common adverse reaction was conjunctival hyperemia (31%).
Subgroup analyses indicated a larger treatment effect in younger patients.
Clinical Implications
Epioxa allows for intervention without the need for epithelium removal, which may enhance patient comfort and expedite recovery.
Conclusion
Epioxa represents a significant advancement in keratoconus treatment.
In their keynote address to the 2026 Global Specialty Lens Symposium, Craig W. Norman and Patrick J. Caroline recounted the evolution of the event over the past 2+ decades.
